載入...
Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series
BACKGROUND: Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free...
Na minha lista:
| 發表在: | Ecancermedicalscience |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Cancer Intelligence
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6214673/ https://ncbi.nlm.nih.gov/pubmed/30483355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2018.875 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|